Press-release for stocks related to lung cancer for amgn

Prices are updated after-hours

tags : Lung cancer symbols : Amgn

save search

Non-small Cell Lung Cancer Drugs Market to Grow by USD 30.23 billion| Increasing Prevalence and Incidence of Non-small Cell Lung Cancer to Boost Market Growth | Technavio
Published: 2022-03-08 (Crawled : 08:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K

Health Technology

| 22.78% | O: -2.09% H: 5.03% C: 0.85%
ALPMY | News | $9.49 -1.11% 480K

Manufacturing

| -40.35% | O: 1.01% H: 0.81% C: -0.06%
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| 17.97% | O: -4.98% H: 0.0% C: 0.0%
ABBV | News | $167.8 -1.03% -0.06% 4.1M

Health Technology

| 14.12% | O: 0.29% H: 0.6% C: -1.24%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -3.62% | O: 3.03% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M

Health Technology

| 23.97% | O: -0.44% H: 0.0% C: 0.0%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| 18.14% | O: 0.35% H: 0.0% C: 0.0%
drug cel lung cancer cancer drug cancer growth

LUMAKRAS® (sotorasib) Receives Approval In Japan For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2022-01-20 (Crawled : 11:00) - biospace.com/
BGNE | $144.0 3.61% 3.48% 220K

Health Technology

| -41.74% | O: 3.95% H: 2.8% C: 1.37%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| 17.03% | O: -0.0% H: 0.0% C: -2.07%
lumakras approval cel lung cancer cancer

LUMYKRAS® (sotorasib) Receives Positive Opinion From EMA CHMP For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
BGNE | $144.0 3.61% 3.48% 220K

Health Technology

| -61.89% | O: 1.02% H: 0.0% C: 0.0%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| 27.99% | O: -0.92% H: 0.0% C: 0.0%
ema lung cancer positive cancer chmp

Labcorp Launches Companion Diagnostic for Amgen’s Newly-approved Lung Cancer Therapy
Published: 2021-07-01 (Crawled : 00:00) - biospace.com/
LH 4 | $207.94 -0.01% 0.0% 790K

Health Services

| -26.03% | O: 0.36% H: 0.61% C: 0.42%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| 12.22% | O: -0.0% H: 1.38% C: 1.3%
lung cancer therapy cancer approval diagnostic

New Drug Effective Against Lung Cancers Caused by Common Genetic Error
Published: 2021-06-04 (Crawled : 19:00) - prnewswire.com
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| Email alert Add to watchlist
new drug genetic lung cancer cancer drug

QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer
Published: 2021-05-28 (Crawled : 21:00) - biospace.com/
QGEN | $41.52 -0.88% 0.0% 820K

Health Technology

| -14.75% | O: 0.59% H: 0.91% C: -0.14%
QGEN | $41.52 -0.88% 0.0% 820K

Health Technology

| -14.75% | O: 0.59% H: 0.91% C: -0.14%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| 16.25% | O: 0.38% H: 1.97% C: 0.73%
fda lung cancer cancer fda approval diagnostic

FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy
Published: 2021-05-28 (Crawled : 17:00) - prnewswire.com
GH | News 4 | $18.1 4.38% 4.2% 1.6M

Health Services

| -86.05% | O: 0.82% H: 2.28% C: -0.95%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| 16.25% | O: 0.38% H: 1.97% C: 0.73%
fda lung cancer therapy cancer drug fda approval approval

FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Published: 2021-05-28 (Crawled : 17:00) - prnewswire.com
BGNE | $144.0 3.61% 3.48% 220K

Health Technology

| -60.4% | O: 0.41% H: 2.09% C: 1.72%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| 16.25% | O: 0.38% H: 1.97% C: 0.73%
treatment fda lung cancer cancer fda approval

Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
Published: 2021-04-19 (Crawled : 13:00) - biospace.com/
BGNE | $144.0 3.61% 3.48% 220K

Health Technology

| -54.51% | O: -0.02% H: 1.91% C: -0.69%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| 6.97% | O: -1.12% H: 1.29% C: 1.23%
lung cancer test cancer biomarkers

BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
Published: 2021-04-12 (Crawled : 20:00) - biospace.com/
BGNE | $144.0 3.61% 3.48% 220K

Health Technology

| -54.91% | O: 0.09% H: 0.0% C: -4.44%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| 9.88% | O: -0.17% H: 0.6% C: 0.17%
lung cancer results cancer trial

FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Published: 2021-02-16 (Crawled : 00:00) - biospace.com/
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| 15.32% | O: -0.51% H: 0.71% C: -1.34%
treatment fda lung cancer cancer designation

Amgen's Investigational KRAS G12C Inhibitor Sotorasib Demonstrated Rapid, Deep And Durable Responses In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Published: 2021-01-28 (Crawled : 20:08) - prnewswire.com
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| 10.41% | O: -1.14% H: 0.63% C: -1.43%
cancer ev lung cancer

Amgen To Webcast Investor Meeting At 2020 World Conference on Lung Cancer
Published: 2021-01-26 (Crawled : 23:00) - biospace.com/
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology